Ana Mulero's Professional Writing Services
More Than One-Third of Biotechs Have Under a Year of Cash Left, EY Finds
More Than One-Third of Biotechs Have Under a Year of Cash Left, EY Finds
More Than One-Third of Biotechs Have Under a Year of Cash Left, EY Finds
EY’s 2025 Biotech Beyond Borders report provides a sobering snapshot of the industry’s financial health, with more and more companies facing cash runways of less than one year. The analyst firm’s leaders urge a return to basics for biotech.
Why Industry Anticipates a ‘Cliff-Edge’ Scenario With EU MDR/IVDR
More Than One-Third of Biotechs Have Under a Year of Cash Left, EY Finds
More Than One-Third of Biotechs Have Under a Year of Cash Left, EY Finds
The EU’s medical device and in vitro diagnostic regulations (MDR/IVDR) may cause a “cliff-edge scenario,” meaning a disruption in the supply of certain medical devices and IVDs, industry groups and the European Commission cautioned.
Opposition to International Pricing Index for Part B Drugs Mounts
More Than One-Third of Biotechs Have Under a Year of Cash Left, EY Finds
FDA to tackle uptick in cell and gene therapy applications with new ‘super office’
A coalition of more than 40 conservative groups led by Americans for Tax Reform urged the Trump administration in 2020 to withdraw its International Pricing Index (IPI) proposal for Medicare Part B drugs.
FDA to tackle uptick in cell and gene therapy applications with new ‘super office’
FDA to tackle uptick in cell and gene therapy applications with new ‘super office’
FDA to tackle uptick in cell and gene therapy applications with new ‘super office’
Looking to maximize efficiency in anticipation of an impending flood of cell and gene therapy applications, CBER will morph its Office of Tissues and Advanced Therapies into a new FDA “super office” dubbed the Office of Therapeutic Products.
FDA approval of aducanumab paves way for Alzheimer’s blood tests
FDA to tackle uptick in cell and gene therapy applications with new ‘super office’
FDA approval of aducanumab paves way for Alzheimer’s blood tests
Developers of blood tests for the early diagnosis of Alzheimer’s disease (AD) are poised to see a spike in demand, following the FDA’s accelerated approval on Tuesday of Cambridge, Mass.-based Biogen Inc.’s AD drug treatment Aduhelm (aducanumab).
Medium company honoree: Cassaday & Co.
FDA to tackle uptick in cell and gene therapy applications with new ‘super office’
FDA approval of aducanumab paves way for Alzheimer’s blood tests
.jpg/:/cr=t:21.16%25,l:0%25,w:100%25,h:33.33%25/rs=w:388,h:194,cg:true)
The Washington Business Journal (WBJ) talked to Stephan Cassaday, president and CEO of Cassaday & Co. about what makes the McLean wealth management firm a Best Places to Work.